Article
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
BMC infectious diseases - 1 Jan 2014
Strazzulla Alessio, Costa Chiara, Pisani Vincenzo, De Maria Vincenzo, Giancotti Francesca, Di Salvo Sebastiano, Parisi Saverio Giuseppe, Basso Monica, Franzetti Marzia Maria, Marascio Nadia, Liberto Maria Carla, Barreca Giorgio Settimo, Lamberti Angelo Giuseppe, Zicca Emilia, Postorino Maria Concetta, Matera Giovanni, Focà Alfredo, Torti Carlo
Abstract excerpt
BACKGROUND: In Italy, anti-HCV drugs are provided free of charge by the National Health System. Since 2011, three drug regimens including a directly acting antiviral (DAA) are considered the gold standard for HCV treatment. However, these drugs add a significant cost (roughly €26,000) to the comb...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.